Herculean mistake: mephentermine associated cardiomyopathy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32404042.
- Also identified by DOI 10.1080/00913847.2020.1763146.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>Case presentation</b>: A 32-year-old professional bodybuilder presented with acute decompensated heart failure. He gave a history of anabolic androgenic steroids (AAS) use for >2 years and mephentermine use for the preceding 3 months. <b>Management</b>: Transthoracic echocardiography showed severe left ventricular (LV) dysfunction with a large pedunculated, mobile thrombus attached to the ventricular apex. The patient had an embolic stroke during the hospital stay, with complete neurological recovery. Following the cessation of mephentermine use, there was a steady improvement in LV function over a follow-up of 2 months. However, at 3 months, his ventricular function showed deterioration, which coincided with mephentermine reuse. <b>Take home message</b>: Though AAS abuse by athletes leading to such a presentation has been documented, to the best of our knowledge, a similar role of mephentermine has not been reported.
Medical subject headings
- Embolic Stroke
- Mephentermine
- Performance-Enhancing Substances
- Testosterone Congeners
- Ventricular Dysfunction, Left
- Weight Lifting